Latest Lenalidomide Stories
UCSF researchers have identified an existing medication that restores key elements of the immune system that, when out of balance, lead to a steady decline in immunity and health as people age.
In early results, all participants responded to treatment with limited side effects ANN ARBOR, Mich., Dec.
A new three-drug combination used to treat the blood cancer multiple myeloma may be effective as a front-line therapy for newly diagnosed patients.
In the news release, Onyx Pharmaceuticals Announces Positive Complete Results From Carfilzomib Phase 2b Study, issued 07-Dec-2010 by Onyx Pharmaceuticals, Inc.
EMERYVILLE, Calif., Dec. 7, 2010 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc.
ROCKVILLE, Md., Dec. 7, 2010 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), today announced the presentation of data for its Phase 2 oncology drug candidate, ENMD-2076 an Aurora A/angiogenic kinase inhibitor.
MORRISTOWN, N.J. and HYDERABAD, India, Dec. 7, 2010 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) and Natco Pharma Limited (BSE: 524816) today confirmed an exclusive, U.S. development and license agreement, to develop and commercialize lenalidomide 5, 10, 15 and 25 mg tablets.
BURLINGTON, Mass., Dec.
NEW YORK, Dec. 6, 2010 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc.
In two Phase 2 studies, perifosine achieves objective responses and high rates of stable disease as a single-agent in the treatment of Chronic Lymphocytic Leukemia (CLL), and in combination with sorafenib in the treatment of relapsed/refractory Hodgkin's Lymphoma (HL) QUEBEC CITY, Dec.
- An armed gangster.